Shelton Capital Management Sells 3,867 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Shelton Capital Management cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 155,582 shares of the biopharmaceutical company's stock after selling 3,867 shares during the quarter. Shelton Capital Management's holdings in Gilead Sciences were worth $14,371,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of GILD. FMR LLC boosted its stake in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Wellington Management Group LLP increased its stake in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at $1,789,254,000. Finally, Invesco Ltd. grew its holdings in shares of Gilead Sciences by 12.9% during the fourth quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock worth $1,041,741,000 after purchasing an additional 1,292,399 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GILD shares. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Trading Up 2.2 %

Shares of GILD stock traded up $2.23 during trading hours on Friday, reaching $103.63. 8,683,683 shares of the stock traded hands, compared to its average volume of 7,493,897. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $129.04 billion, a PE ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. The business has a fifty day moving average price of $108.34 and a 200 day moving average price of $96.79.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a dividend of $0.79 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. Gilead Sciences's payout ratio is presently 854.05%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.